AFMD - Affimed N.V.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Affimed Q3 2023 Earnings Preview
• Affimed announces listing transfer to Nasdaq Capital Markets
• Affimed gains on FDA fast track tag for lymphoma therapy
• Affimed GAAP EPS of -€0.20, revenue of €1.4M
• Affimed Q2 2023 Earnings Preview
• Russell 3000 rejig: InMode, Assertio among healthcare additions; Inovio, Bionano among deletions
• Affimed gains FDA clearance to study lymphoma candidate
• Affimed GAAP EPS of -€0.21, revenue of €4.51M
• Affimed Q1 2023 Earnings Preview
• Affimed receives non-compliance letter from Nasdaq
• Affimed starts dosing of blood cancer drug in early-stage trial
• Affimed hits new 52-week low after Q4 2022 results
• Affimed GAAP EPS of -€0.60, revenue of €41.35M
• Affimed FY 2022 Earnings Preview
• AbCheck develops microfluidics tech for antibody discovery under Czech grant pact
• AbCheck teams up to use microfluidics tech to discover antibodies for neurological disorder
• Affimed receives approval to begin human trial for acute myeloid leukemia therapy in France
• Affimed drops ~26% after plans to prioritize lead asset as a combination therapy
• Affimed GAAP EPS of -€0.11, revenue of €14.9M
• Affimed ticks higher after updating Phase 1/2 data for tumor candidate